Co-Founder
BOLD Longevity Growth
Co-Founder
BOLD Longevity Growth
Co-Founder
BOLD Longevity Growth
Investment team
Partner & Head of Investments
BOLD Longevity Growth
Partner & Head of Science
BOLD Longevity Growth
Senior Scientific Advisor
BOLD Longevity Growth
Associate
BOLD Longevity Growth
Operating Partner
BOLD Capital
Principal
BOLD Capital
Scientific Advisory Board
-
To be announced soon
Venture Advisory Board
-
To be announced soon
Founders
Sergey Young
Sergey Young is a longevity investor and visionary with a mission to extend the healthy lifespans of at least one billion people and make longevity more affordable and accessible to everyone. Following 20 years of investment expertise managing PE & VC funds, Sergey founded Longevity Vision Fund (LVF) in 2019 to invest in leading biotech companies targeting the underlying causes of aging.
LVF has grown its portfolio to 18 companies across therapeutic platforms, AI-enabled drug discovery, and diagnostics. LVF was honored as a World Changing Idea in Impact Investing by Fast Company in 2021 and 2022, along with the top 15 leading impact investing funds.
Sergey is on the Board of Directors of the American Federation of Aging Research (AFAR) and an Innovation Board Member at XPRIZE. Sergey is also transforming the world, one workplace at a time, with his initiative Longevity@Work – the first non-profit corporate longevity program of its kind.
As the author of the bestselling book, ‘The Science and Technology of Growing Young’, Sergey has been featured as a top longevity expert and contributor on CNN, Fox News, and Forbes.
Teymour Boutros-Ghali
Teymour is a Co-Founder & Managing Partner at BOLD. He has over 30 years of investing and entrepreneurial experience, founding disruptive technologies across corporate and traditional venture capital, biotech and tech startups.
Prior to establishing BOLD Capital, Teymour was a GP at Monitor Ventures, a venture capital fund co-founded by Michael Porter, an American academic. Previously, he was also a Vice President of Time Inc. Ventures (corporate venture fund)
As a CEO in previous organizations, Teymour led 3 companies to and through acquisitions from top industry players, including AllBusiness (which was sold to NBC), Zowie Entertainment (acquired by LEGO) and Thrive Online (sold to AOL).
A graduate of Cambridge University in EE with a PhD from MIT, he has a deep interest in disruptive technologies and has lectured on entrepreneurship at UCLA.
Peter Diamandis
Peter is a Co-Founder & Partner at BOLD. He has over 30 years of investing and entrepreneurial experience, including starting over 20 companies in the areas of longevity, space, venture capital and education.
He is the Founder & Executive Chairman of the XPRIZE Foundation, leading the world in large-scale technology competitions, including the recently launched Healthspan XPRIZE with over $140m in funding. He is also the Executive Founder of Singularity University, a global learning and innovation platform offering executive educational programs.
Peter has been named one of the "World's 50 Greatest Leaders” by Fortune Magazine. Peter is a NY Times bestselling author of four books. Most recently he co-authored Lifeforce with Tony Robbins which chronicles the extraordinary healthcare and biotech revolution unfolding before our eyes.
He earned degrees in molecular genetics and aerospace engineering from MIT and holds an M.D. from Harvard Medical School. Diamandis’ favorite saying is “The best way to predict the future is to create it yourself.”
Investment Team Biographies
Avik Arakelian
Partner & Head of Investments
Avik brings 10+ years of managerial experience in PE & VC investments into pioneering companies across biotech and health tech sectors. He has managed a wide range of investments from venture creation stages to IPOs.
Avik has led and advised investments in more than 25 biotech and longevity companies across gene editing, AI drug discovery, cell and regenerative therapies, and early-stage diagnostics. These investments resulted in several exits through IPOs and M&As, as well as several companies reaching pre-IPO stages, and becoming unicorns.
He was involved in strategic and licensing deals for novel autoimmune and cancer treatments with some of the large pharmaceutical companies as well as leading universities in the US and EU.
Earlier in his career, he advised large corporations on significant M&A deals and management consulting projects at PwC and KPMG across diverse sectors.
Kris Verburgh
Partner & Head of Science
Kris is a medical doctor, author, researcher and inventor specialized in aging and longevity, as well as in the latest developments in medicine and biotechnology.
He wrote his first science book when he was 16 years old, and by age 28 he had written four science books which sold over half a million copies. His most recent international bestselling book “The Longevity Code” explores human life extension and new developments in biotechnology.
Kris created a new scientific field, nutrigerontology, that studies how nutrition influences aging and the risk of age-realted diseases such as heart disease and dementia.
He has given talks and advised large institutions about science, health and technology. He gave lectures for the European Parliament, Cambridge University, Singularity University, international conferences, as well as various academic, corporate and governmental organizations, including Fortune 100 companies and international banks.
Kris is also a researcher and Member of Evolution, Complexity and Cognition (ECCO) Institute at the Free University Brussels where he studies aging and how biotech and lifestyle can improve health and lifespan.
Sun Altbach
Senior Scientific Advisor
Sun is a biopharmaceutical executive and an entrepreneur with 20 years of experience.
Previously she helped develop their Medical Affairs function at Biogen, a biotech pioneer building innovative therapies for neurological and neurodegenerative diseases with a $40B market cap. She also was the Head of Research and Nonclinical Operations at Genzyme, acquired by Sanofi for $20B, where she also oversaw the research portfolio. She was also the founding CEO of PIC Therapeutics, a biotechnology company changing how we treat cancer by developing a new generation of therapeutics based on the modulation of RNA translation.
Currently she is also an Advisory Board Member at The Termeer Foundation and a member of Women In Bio association.
Gunner Hardy
Associate
Gunner is an investment professional with experience in banking, start-up advisory, and genetics research. His background also extends into academic research in genomics and bioinformatics.
Previously, he worked in banking at BofA Merrill Lynch, World Bank, and the EBRD focusing on private company investments covering origination, structuring, execution, and implementation.
He was formerly an Analyst at Conscience VC, a seed-stage venture capital fund investing across biotech, health, and wellness. Additionally, he worked for VITA DAO, a longevity-focused research organization funding emerging research in combatting aging.
Helen McBride
Operating Partner, BOLD Capital
Helen McBride brings 20+ years of experience in healthcare and life sciences to her role as an Operating Partner at BOLD. Her career includes 13+ years at Amgen, most recently as Director of Research focusing on Inflammation and Oncology therapeutics, and a position leading translational sciences at oncology start-up TORL Biotherapeutics.
As an investor, Helen led healthcare investing at the Fund@Caltech, seed fund of Caltech, contributing to several successful spinouts. Her interests include integrating physics with biology, novel target discovery, and supporting therapeutic advancements.
She holds a BS in Microbiology from Texas A&M University, a PhD in Oncological Sciences from the University of Utah, and completed postdoctoral training at Caltech in developmental neurobiology and biophysics.
Will Borthwick
Principal, BOLD Capital
Will has 10+ years of experience from investment banking, private equity, and venture capital. He is a principal at BOLD Capital. He worked previously at Marlin Equity Partners, a software and technology-focused private equity firm. Prior to that, Will worked in investment banking at Morgan Stanley where he participated in several mergers & acquisitions and strategic advisory assignments.
Will’s background and expertise extend across AI/machine learning, tech-enabled clinical trial optimization, blockchain, imaging and diagnostic tools, and AR/VR.
He graduated with a BA in Economics with a minor in American Studies from Stanford University.